Premenstrual Dysphoric Disorder

2
Pipeline Programs
2
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
PAROXETINE MESYLATEApproved
paroxetine
Unknown Company
oral2017

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
paroxetinePhase 41 trial
Active Trials
NCT00516113Completed24Est. Nov 2002
UP
UCB PharmaBelgium - Brussels
1 program
LevetiracetamN/A1 trial
Active Trials
NCT00518570Completed7Est. Oct 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo Nordiskparoxetine
UCB PharmaLevetiracetam

Clinical Trials (2)

Total enrollment: 31 patients across 2 trials

NCT00516113Novo Nordiskparoxetine

A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria

Start: Oct 2000Est. completion: Nov 200224 patients
Phase 4Completed
NCT00518570UCB PharmaLevetiracetam

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

Start: Nov 2003Est. completion: Oct 20067 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space